Nociception

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

Retrieved on: 
Thursday, June 10, 2021
Nervous system, Branches of biology, Symptoms and signs, Pain, Nociception, Acute pain, Neuropathic pain, Peripheral neuropathy

Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.

Key Points: 
  • Professor Dougherty and Professor Dworkin will advise OliPass on Phase 2 clinical trials of OLP-1002.
  • Considering the pharmacological complexity of neuropathic pain, however, expertise in neuropathic pain and in clinical study design will be critical to a success in the clinical development of OLP-1002 against neuropathic pain.
  • We are very much honored to have Professor Dougherty and Professor Dworkin as new SAB members as we develop the first-in-class pain killer.
  • He has significantly contributed to defining mechanism of cancer therapy-induced pain and identifying potential therapeutic interventions for its relief or prevention.

RYAH Group, Inc Publishes Report on Medical Cannabis Use for Pain

Retrieved on: 
Thursday, June 10, 2021
Pain, Branches of biology, Medicine, Herbalism, Medicinal plants, Nociception, Acute pain, Palliative care, Medical cannabis, Cannabis, Chronic pain, Opioid

TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc. (CSE:RYAH) (RYAH or the Company) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. ("RYAH Medtech"), has published a data report on use of medical cannabis among patients with pain conditions.

Key Points: 
  • TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc. (CSE:RYAH) (RYAH or the Company) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. ("RYAH Medtech"), has published a data report on use of medical cannabis among patients with pain conditions.
  • The data report features insights into the use of cannabis to treat pain conditions by patients within the RYAH Data ecosystem and whether cannabis may be one of the alternative treatment solutions to reduce opioid use-related problems associated with existing treatment options.
  • The RYAH data report on cannabis use for pain management comes at a turning point as studies on alternatives to opioids in treatment and potential efficacy of chronic pain start to accelerate, says Gregory Wagner, CEO of RYAH.
  • RYAH Group, Inc. (RYAH) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry.

PainQx Awarded $1.5M Phase II SBIR Contract from the Defense Health Agency SBIR Program to Refine Objective Pain Assessment Technology

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Pain, Medicine, Nociception, Pain management, Electrophysiology, Neurophysiology, Electroencephalography, Small Business Innovation Research, Chronic pain, Algos

The DHA SBIR contract will enable PainQx to refine and expand the capabilities of its novel pain assessment technology, the ALGOS System.

Key Points: 
  • The DHA SBIR contract will enable PainQx to refine and expand the capabilities of its novel pain assessment technology, the ALGOS System.
  • The PainQx ALGOS System is an AI-enabled software platform that uses electroencephalogram (EEG) derived neural activity to objectively assess pain.
  • The data is processed through a series of proprietary algorithms to generate a scaled chronic pain biomarker correlating to a patients pain.
  • The DHA SBIR contract will enable PainQx to build upon the success of previously awarded National Institute on Drug Abuse (NIDA) Phase I and Phase II SBIR award for the Development of a Device to Objectively Measure Pain.

Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Retrieved on: 
Wednesday, June 9, 2021
Pain, Medicine, Branches of biology, Nociception, Pain management, Health informatics, Acute pain, Pain scale, Chronic pain, Cognitive behavioral therapy, Promis, SAMD

Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).

Key Points: 
  • Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale).
  • Cognitive Behavioral Therapy (CBT) is scientifically sound, effective and a recommended method to improve the self-management of chronic pain.
  • Orion is looking for a partner to further develop and commercialise Orions digital therapeutics software solution for Chronic Pain.
  • Orions DTxP, aimed to be a software as medical device (SaMD), is built for virtual reality (VR) devices to provide an immersive gamified therapeutic treatment program for the chronic pain patients.

New App Arms People with Strategies to Fight Chronic Pain, Live a Fuller Life

Retrieved on: 
Tuesday, June 8, 2021
Software, Text editors, Pain, Acute pain, Nociception, Pain management, Suffering, Vim, Chronic pain, Chronic condition

Named Vim , a word defined by "energy" and "enthusiasm," the app is a direct response to the chronic pain reported by patients in the Arthritis Foundation's ongoing Live Yes!

Key Points: 
  • Named Vim , a word defined by "energy" and "enthusiasm," the app is a direct response to the chronic pain reported by patients in the Arthritis Foundation's ongoing Live Yes!
  • Vim arms users with personalized pain management strategies and serves as a pocket-friendly way of tracking pain to help facilitate conversations with their doctor.
  • The all-in-one app is also a master motivator encouraging people to set attainable movement goals and rewarding them for their wins.
  • "Our research shows that chronic pain is pervasive affecting every aspect of a patient's life," said Taylor.

Kailo Launches Channel Partner Program in North America and Europe With a Goal to Help as Many People as Possible With Pain Relief Management

Retrieved on: 
Tuesday, June 8, 2021
General Health, Medical devices, Other Retail, Health, Retail, Nervous system, Pain, Branches of biology, Acute pain, Nociception, Suffering, Kailo Territory

Pain Relief Technologies LLC, manufacturers of the Kailo Pain Patch that has helped millions of pain sufferers around the world, today launched the Kailo Partner Program aimed to bring in resale partners across North America and Europe.

Key Points: 
  • Pain Relief Technologies LLC, manufacturers of the Kailo Pain Patch that has helped millions of pain sufferers around the world, today launched the Kailo Partner Program aimed to bring in resale partners across North America and Europe.
  • Pain Relief Technologies is a Company founded on its commitment to help as many people as possible live their best lives without the interference of pain.
  • PAIN RELIEF TECHNOLOGIES LLC, based in Sandy, Utah, manufactures and distributes the Kailo Pain Patch as part of its portfolio of pain products to millions of pain sufferers around the world.
  • Kailo - The Future of Pain Relief is a
    nanotech bio-antenna that interacts with electrical signals in your body, naturally relieving pain.

Canadians living with mental health conditions stand to save over $57 billion with use of pharmacogenetic testing

Retrieved on: 
Tuesday, June 8, 2021
Pain, Branches of biology, Medicine, Suffering, Nociception, Acute pain, Pain management, Chronic pain, Mental health, Chronic condition, Mental disorder

Pain and mental health conditions were significant issues prior to the COVID-19 pandemic, but this past year has resulted in an explosion of mental health conditions in Canada2 and around the world, and people with chronic pain have seen their condition worsen3.

Key Points: 
  • Pain and mental health conditions were significant issues prior to the COVID-19 pandemic, but this past year has resulted in an explosion of mental health conditions in Canada2 and around the world, and people with chronic pain have seen their condition worsen3.
  • Canada must determine a better way to effectively support the growing number of people seeking treatment for new and existing pain and mental health conditions.
  • Inagene and Calian plan to collaborate to drive awareness of pharmacogenetic testing, and the power it holds to transform the journey and outcomes of those diagnosed with mental health or pain conditions.
  • Reducing the time and cost of trialing medications for pain management and mental health treatment has the potential to significantly improve the well-being of Canadians.

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Thursday, June 3, 2021
Pain, Branches of biology, Medicine, Nociception, Fibromyalgia, Rheumatology, Sensory systems, Acute pain, Chronic pain, Tonix Pharmaceuticals

Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system.

Key Points: 
  • Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system.
  • Fibromyalgia afflicts an estimated 6-12 million adults in the U.S., approximately 90% of whom are women.
  • Tonixs lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, with positive data from the Phase 3 RELIEF study reported in December 2020.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products.

Professional Snowboarder Jake Vedder Joins Nutra Pharma in Endorsing Nyloxin for Chronic Pain Relief

Retrieved on: 
Wednesday, June 2, 2021
Pain, Nervous system, Branches of biology, Acute pain, Opioids, Nociception, Palliative care, Pain management, Analgesic, Heroin

Nutra Pharma announces that professional snowboarder and wakeboarder, Jake Vedder, is endorsing Nyloxin for Chronic Pain Relief as part of their social media and influencer campaign

Key Points: 
  • "As a high-level athlete, it is super important that out bodies are always moving and feeling good every day," commented snowboarder Jake Vedder.
  • It's also important to me that Nyloxin is all-natural and easy to add to my routine," he continued.
  • Nyloxin is a safe, non-narcotic, and non-addictive Homeopathic pain reliever for the relief of pain without impairing cognitive function.
  • Nyloxin is available as an oral spray for systemic pain and as a topical gel for targeted pain management.

Meeting Report Published in Journal of Pain Research Explores Dental Pain Management and Opioid Prescribing During and Beyond COVID-19 Pandemic

Retrieved on: 
Monday, May 31, 2021
Branches of biology, Nervous system, Pain, Acute pain, Palliative care, Nociception, Orofacial pain, Pain management, Opioid, Journal of Pain Research, The Journal of Pain, Beth Darnall

NEW YORK, May 31, 2021 /PRNewswire-PRWeb/ --A new meeting report published in the Journal of Pain Research explores pain management and opioid prescribing in dentistry during and beyond the COVID-19 Pandemic.

Key Points: 
  • NEW YORK, May 31, 2021 /PRNewswire-PRWeb/ --A new meeting report published in the Journal of Pain Research explores pain management and opioid prescribing in dentistry during and beyond the COVID-19 Pandemic.
  • Topics discussed include Precision Medicine for Orofacial Pain Management, Substance Risk Assessments in Dentistry, Opioid Moderatism and Opioid Sparing in Children and Adolescents.
  • To read the full meeting report please visit: https://www.dovepress.com/pain-management-for-dental-medicine-in-2021-op...
    The Journal of Pain Research is an international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain.
  • The Journal of Pain Research is the official journal of the American Society of Pain & Neuroscience.